Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
about
Gene therapy for carcinoma of the breast: Genetic immunotherapyGene therapy for brain tumors: basic developments and clinical implementationInterleukin 12: still a promising candidate for tumor immunotherapy?Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes.Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of miceNew insights into IL-12-mediated tumor suppression.Gene therapy for paediatric leukaemia.Chemokines: agents for the immunotherapy of cancer?Interleukin-27 signaling promotes immunity against endogenously arising murine tumors.Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis.Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.Immune cell recruitment and cell-based system for cancer therapy.Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12Adenoviral vector-based strategies for cancer therapy.Chemokine-chemokine receptors in cancer immunotherapy.Bacteria as vectors for gene therapy of cancer.Chemokine-based immunotherapy: delivery systems and combination therapies.Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer.Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors.Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity.Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.Inducing neutrophil recruitment in the liver of ICAM-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1.IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency.The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.Interaction analysis of IL-12A and IL-12B polymorphisms with the risk of colorectal cancer.Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct.
P2860
Q24797848-3BB27CCD-A32E-4151-87D8-84090A62C0E0Q26829086-F3A7D622-D20D-47E8-8432-C826C760E29EQ26861559-853E01F4-2452-437D-B2AC-9A399D2C4166Q33939602-593014FF-9F29-4A1C-8649-E143D16E2393Q34292653-E3F7F9BA-0D45-4C97-9A7E-4AF365FC9868Q34436897-4EB533E4-F0B0-4F52-B398-4113145C2CF4Q34451905-9CC0899F-C46D-4AAA-ADF7-80E55C5E85BFQ34576416-5334EF3A-D995-4636-8B8E-C5667638D585Q34647840-25663A63-B1DA-437D-82F0-8D3EAC3A4E51Q36308400-D8BE06EA-3391-4002-A5F4-EFA3A7AC31A1Q36422849-364420A4-2FC7-4F71-B212-AE926B46511AQ36517706-ED80B886-8B67-4427-86E5-452C0AF6DA03Q36610857-BCB618A6-BF89-496D-9837-C10C4BF6C77EQ37409025-9640D39E-BF89-4268-89A4-A67BB441775CQ37773282-3B44D8F9-0B91-4599-890A-ABDEAF1F7AC6Q37862087-3CE083C9-7FB3-4977-A3F9-DDDBFB780905Q38040509-5F3AC966-D623-43D8-B80D-1D41A2C1E75BQ38522757-33D29B21-05DB-4004-B857-4394EFE46815Q39607063-35B60C99-36F6-4672-AC9E-B2D4472F647AQ40187064-FF7FFF65-1AB1-420A-BEC3-F55B36F4EA84Q40435764-5D4ACDDE-BBFF-4DB8-A5C0-1952C488D65AQ40729470-0CB9FA7D-29A0-4DB8-BB85-A67B9022CBEBQ41901023-5D932054-3E6C-49AB-BC5B-D1A7E1C2C7CFQ45876491-83EBB874-DF1D-479A-A70A-672A43F14E74Q45886594-E841390C-8FBE-41D7-8ECF-E6D8028681B2Q45887333-5D638F56-B2D4-47A6-AA37-25BC67487057Q47373704-E5CB1CE8-5C09-4645-8B0B-A99D957E3034Q47658796-624792A4-8711-49D1-B8DB-F25C3094E7D4Q53456887-EAE8ADF2-C653-4686-BD9C-9A2C90EEBEF0Q54573260-66DC416A-286B-47AE-9528-E07652090B51
P2860
Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Adenoviral vectors expressing ...... n murine breast cancer models.
@en
type
label
Adenoviral vectors expressing ...... n murine breast cancer models.
@en
prefLabel
Adenoviral vectors expressing ...... n murine breast cancer models.
@en
P2093
P1433
P1476
Adenoviral vectors expressing ...... n murine breast cancer models.
@en
P2093
P304
P356
10.1089/10430349950018463
P577
1999-03-01T00:00:00Z